A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies
CRISPR Therapeutics
CRISPR Therapeutics
Prelude Therapeutics
M.D. Anderson Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
Case Comprehensive Cancer Center
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
Takeda
The Lymphoma Academic Research Organisation
Ohio State University Comprehensive Cancer Center
Masonic Cancer Center, University of Minnesota
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Masonic Cancer Center, University of Minnesota
Mayo Clinic
Children's Oncology Group
City of Hope Medical Center
SecuraBio
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Ohio State University Comprehensive Cancer Center
Massachusetts General Hospital
Takeda
M.D. Anderson Cancer Center
Beijing Boren Hospital
Advice Pharma Group srl
BeiGene
Northwestern University
Kyowa Kirin Co., Ltd.
Memorial Sloan Kettering Cancer Center
Emergent BioSolutions
VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
University of Nebraska
Stanford University
City of Hope Medical Center
University of Nebraska
Columbia University
GWT-TUD GmbH
Memorial Sloan Kettering Cancer Center
National Institutes of Health Clinical Center (CC)
Rhizen Pharmaceuticals SA
National Institutes of Health Clinical Center (CC)
Alexion Pharmaceuticals, Inc.
National Institutes of Health Clinical Center (CC)
Seagen Inc.
National Institutes of Health Clinical Center (CC)
AstraZeneca
The Lymphoma Academic Research Organisation
Stanford University